1. Home
  2. LGND vs DYN Comparison

LGND vs DYN Comparison

Compare LGND & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • DYN
  • Stock Information
  • Founded
  • LGND 1987
  • DYN 1984
  • Country
  • LGND United States
  • DYN United States
  • Employees
  • LGND N/A
  • DYN N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • DYN Medicinal Chemicals and Botanical Products
  • Sector
  • LGND Health Care
  • DYN Health Care
  • Exchange
  • LGND Nasdaq
  • DYN Nasdaq
  • Market Cap
  • LGND N/A
  • DYN 2.6B
  • IPO Year
  • LGND 1992
  • DYN 2020
  • Fundamental
  • Price
  • LGND $107.62
  • DYN $11.45
  • Analyst Decision
  • LGND Strong Buy
  • DYN Strong Buy
  • Analyst Count
  • LGND 6
  • DYN 12
  • Target Price
  • LGND $145.00
  • DYN $47.73
  • AVG Volume (30 Days)
  • LGND 135.2K
  • DYN 1.8M
  • Earning Date
  • LGND 05-06-2025
  • DYN 05-01-2025
  • Dividend Yield
  • LGND N/A
  • DYN N/A
  • EPS Growth
  • LGND N/A
  • DYN N/A
  • EPS
  • LGND N/A
  • DYN N/A
  • Revenue
  • LGND $167,133,000.00
  • DYN N/A
  • Revenue This Year
  • LGND $16.90
  • DYN N/A
  • Revenue Next Year
  • LGND $18.27
  • DYN N/A
  • P/E Ratio
  • LGND N/A
  • DYN N/A
  • Revenue Growth
  • LGND 27.28
  • DYN N/A
  • 52 Week Low
  • LGND $67.72
  • DYN $10.72
  • 52 Week High
  • LGND $129.90
  • DYN $47.45
  • Technical
  • Relative Strength Index (RSI)
  • LGND 44.36
  • DYN 38.48
  • Support Level
  • LGND $106.79
  • DYN $10.72
  • Resistance Level
  • LGND $112.49
  • DYN $12.43
  • Average True Range (ATR)
  • LGND 4.58
  • DYN 0.70
  • MACD
  • LGND 0.12
  • DYN 0.07
  • Stochastic Oscillator
  • LGND 43.87
  • DYN 34.93

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

Share on Social Networks: